Date: Saturday, June 2, 2018
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall 4EF
Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented. However, trial of association of plasma exchange with anti-rejection therapy in the early cyclosporine era was not successful.
Aim: To compare the effect of transplant recipients' plasma and healthy controls' plasma on lymphocyte activation according to immunosuppressive drugs.
Peripheral blood mononuclear cells (PBMC) were separated from the blood samples of healthy controls and kidney transplant patients on cyclosporine, tacrolimus and sirolimus, based regimens by density gradient centrifugation. Cells were counted and incubated overnight with and without phytohemagglutinin (PHA) ± plasma. The luciferin-luciferase enzyme reaction that induces bioluminescence and the Turner Biosystem luminometer were used to measure intracellular ATP levels in relative light units (RLU) and converted to ng/ml using an ATP standard curve. According to normality test results, parametric or non-parametric tests from Instat 3 program (GraphpadR) were performed to compare various group results. Demographic and clinical parameters and immunosuppressive blood levels were measured. Logistic regression analysis was performed using SPSS program version 25 (IBM).
PHA stimulation of PBMC from healthy individuals produced a 47% increase ATP production. The ATP increase is reduced to 14% when normal plasma was added (p<0.05). However, when normal plasma was replaced by patient plasma, the ATP increase was reduced only to 31%. While lymphocyte from all transplants patients were supressed by control plasma, those from patients on tracrolimus were even more supressed (ATP level: 1252.30±64.07ng/ml) than those on cyclosporine or sirolimus (ATP level: 1915.29±149.94 ng/ml, and 1834.10±151.39 ng/ml respectively) (p=0.0388, ANOVA). Logistic regression analysis revealed that plasma inhibition was greatest in lymphocytes from patients on tacrolimus OR(CI) 1.003(1.000-1.007), (p=0.036).
Resulting from this study, we propose that plasma exchange with selected control plasma with the greatest potency in T cell inhibition, be evaluated as part of anti-rejection treatment, especially in patients on tacrolimus based regimen.
CITATION INFORMATION: Assounga A., Omarjee S. The Inhibitory Effect of Plasma on Activation of Lymphocytes from Kidney Transplants is Significantly More Severe in Tacrolimus Based Regimen: What Implications for Plasma Exchange Role in Anti-Rejection Therapy? Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Assounga A, Omarjee S. The Inhibitory Effect of Plasma on Activation of Lymphocytes from Kidney Transplants is Significantly More Severe in Tacrolimus Based Regimen: What Implications for Plasma Exchange Role in Anti-Rejection Therapy? [abstract]. https://atcmeetingabstracts.com/abstract/the-inhibitory-effect-of-plasma-on-activation-of-lymphocytes-from-kidney-transplants-is-significantly-more-severe-in-tacrolimus-based-regimen-what-implications-for-plasma-exchange-role-in-anti-reject/. Accessed March 8, 2021.
« Back to 2018 American Transplant Congress